Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
about
Antiretroviral therapy response among HIV-2 infected patients: a systematic reviewFirst-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaborationAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsUpdate on human immunodeficiency virus (HIV)-2 infection.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?Special aspects of the treatment of HIV-2-infected patients.Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.Mortality and survival patterns of people living with HIV-2Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance
P2860
Q27003854-3693F5AA-0130-465B-9D16-9A4EC95FF980Q33891896-3382E16E-284E-462C-B3BA-ADD40FE5389BQ34730950-A5A72822-8095-4EFA-AA0D-25B122A1016CQ35019924-30AE1F7B-FF02-475C-AB31-9135A2087C72Q35770848-B6BF886D-881A-46E1-8612-08A528152F84Q36564668-BA999B7D-79E3-4134-837F-AACAE825B553Q37026564-C7520622-15FB-4EA8-9E35-DCB83F27838EQ37845847-BAB255F5-9348-4B1D-9895-638F51006909Q37979706-877A325E-F6CF-4874-A22E-831D87CDC574Q38820118-48A1BBCE-761B-43A5-82BE-ABD8C69787D8Q38851677-1F417B15-F652-4CDD-8600-212AE032C82BQ44990505-8662460B-579E-4AEF-AD22-4E98B4D8532FQ48240350-D5DD9806-86A5-4556-83E9-42BD3FCD0436Q52595330-3DBF7BE6-6838-4965-86F4-16A9760A4559Q52625498-05C0F128-DE8A-4CE9-B4E3-197339153BB5Q58391480-04FD429F-8D25-48E2-A736-C55C451CFEC1
P2860
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@en
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@nl
type
label
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@en
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@nl
prefLabel
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@en
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@nl
P2093
P50
P1433
P1476
Good response to lopinavir/rit ...... naive HIV-2-infected patients.
@en
P2093
ANRS CO5 HIV-2 Cohort Study Group
Antoine Bénard
Audrey Taieb
Brigitte Autran
Caroline Lascoux-Combes
François Simon
Pauline Campa
P304
P356
10.1097/QAD.0B013E32832949F0
P407
P577
2009-06-01T00:00:00Z